QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.104.076877v1 312/3/1206    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gierse, J. K. Articles by Seibert, K. Search for Related Content PubMed PubMed Citation Articles by Gierse, J. K. Articles by Seibert, K. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

INFLAMMATION AND IMMUNOPHARMACOLOGY

Valdecoxib: Assessment of Cyclooxygenase-2 Potency and Selectivity

Pfizer Research, Chesterfield, Missouri

The discovery of a second isoform of cyclooxygenase (COX) led to the search for compounds that could selectively inhibit COX-2 in humans while sparing prostaglandin formation from COX-1. Celecoxib and rofecoxib were among the molecules developed from these efforts. We report here the pharmacological properties of a third selective COX-2 inhibitor, valdecoxib, which is the most potent and in vitro selective of the marketed COX-2 inhibitors that we have studied. Recombinant human COX-1 and COX-2 were used to screen for new highly potent and in vitro selective COX-2 inhibitors and compare kinetic mechanisms of binding and enzyme inhibition with other COX inhibitors. Valdecoxib potently inhibits recombinant COX-2, with an IC₅₀ of 0.005 µM; this compares with IC values of 0.05 µM for celecoxib, 0.5 µM for rofecoxib, and 5 µM for etoricoxib. Unique binding interactions of valdecoxib with COX-2 translate into a fast rate of inactivation of COX-2 (110,000 M/s compared with 7000 M/s for rofecoxib and 80 M/s for etoricoxib). The overall saturation binding affinity for COX-2 of valdecoxib is 2.6 nM (compared with 1.6 nM for celecoxib, 51 nM for rofecoxib, and 260 nM for etoricoxib), with a slow off-rate (t_1/2 98 min). Valdecoxib inhibits COX-1 in a competitive fashion only at very high concentrations (IC₅₀ = 150 µM). Collectively, these data provide a mechanistic basis for the potency and in vitro selectivity of valdecoxib for COX-2. Valdecoxib showed similar activity in the human whole-blood COX assay (COX-2 IC₅₀ = 0.24 µM; COX-1 IC₅₀ = 21.9 µM). We also determined whether this in vitro potency and selectivity translated to significant potency in vivo. In rats, valdecoxib demonstrated marked potency in acute and chronic models of inflammation (air pouch ED₅₀ = 0.06 mg/kg; paw edema ED₅₀ = 5.9 mg/kg; adjuvant arthritis ED₅₀ = 0.03 mg/kg). In these same animals, COX-1 was spared at doses greater than 200 mg/kg. These data provide a basis for the observed potent anti-inflammatory activity of valdecoxib in humans.

Address correspondence to: James K. Gierse, Arthritis and Inflammation Pharmacology, Pfizer Research, 700 Chesterfield Parkway West, Chesterfield, MO 63017. E-mail: james.k.gierse{at}pfizer.com

This article has been cited by other articles:

				A. M. Simon and J. P. O'Connor Dose and Time-Dependent Effects of Cyclooxygenase-2 Inhibition on Fracture-Healing J. Bone Joint Surg. Am., March 1, 2007; 89(3): 500 - 511. [Abstract] [Full Text] [PDF]

				C. Brenneis, T. J. Maier, R. Schmidt, A. Hofacker, L. Zulauf, P.-J. Jakobsson, K. Scholich, and G. Geisslinger Inhibition of prostaglandin E2 synthesis by SC-560 is independent of cyclooxygenase 1 inhibition FASEB J, July 1, 2006; 20(9): 1352 - 1360. [Abstract] [Full Text] [PDF]

				E. Fosslien Cardiovascular Complications of Non-Steroidal Anti-Inflammatory Drugs Ann. Clin. Lab. Sci., October 1, 2005; 35(4): 347 - 385. [Abstract] [Full Text] [PDF]